NANOVIRICIDES INC

Investor insight: Noble Capital rates NanoViricides (NNVC) Outperform after Phase II trial launch of NV‑387 Oral Gummies for Bundibugyo Ebola—unique oral therapy, broad‑spectrum antiviral, potential upside for shareholders.

NanoViricides raises $85 M in a public offering to fund clinical trials and expand manufacturing, aiming to deliver breakthrough viral‑infection treatments faster.

NanoViricides, Inc. is a biopharmaceutical company focused on developing treatments for challenging viral diseases, such as AIDS/HIV and influenza, through innovative research and dedication to improving global health.

NanoViricides, Inc. is a biopharmaceutical company advancing research in viral treatment solutions for diseases such as AIDS/HIV, Hepatitis C, and influenza.

NanoViricides, Inc. is a biopharmaceutical company pioneering antiviral treatments for diseases such as AIDS/HIV, Hepatitis C, and influenza, with a focus on improving global health outcomes through scientific excellence.

NanoViricides, Inc. will showcase its innovative research and development efforts at the BIO International Convention in Boston on June 16, 2025, highlighting its progress in fighting viral diseases.

NanoViricides Inc. is advancing its lead candidate, NV-387, a broad-spectrum antiviral with potential to combat multiple viral threats, despite facing financial challenges in its development and Phase II trials.

NanoViricides Inc. is a biopharmaceutical company developing broad-spectrum antivirals using innovative nanomedicine technology, offering a promising solution to combat global viral threats such as measles and MPox.

NanoViricides Inc. is developing a broad-spectrum antiviral treatment, NV-387, to combat the rising threats of measles and MPox, with plans to make it available to licensed physicians.